Astellas Culls Positions Ahead Of Big Expiry
Astellas is looking to cut hundreds of positions in Japan as it faces a major upcoming patent expiry and refocuses under a new strategic plan.
You may also be interested in...
Japanese firm unveils new capital investment program for novel biologics including antibodies and cell therapies as it ups full-year forecasts on strong US and global growth for Xtandi after a solid first half.
Protocol changes for the Phase III ARCHES and EMBARK trials will deliver results in hormone-sensitive prostate cancer a year and a half earlier than expected. Xtandi may then gain a valuable new indication sooner than anticipated, but generics for competitor Zytiga could launch before then.
Astellas’ late-stage bet on Aquinox’s urology drug now looks highly unlikely to pay off following the molecule’s “definitive” failure in a Phase III trial, which is also forcing the originator to consider its business and R&D options.